Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 4.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,757 shares of the company’s stock after selling 3,813 shares during the period. Mutual of America Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $5,428,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. McGlone Suttner Wealth Management Inc. purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $28,000. Point72 Middle East FZE purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $50,000. Ronald Blue Trust Inc. grew its stake in Amphastar Pharmaceuticals by 821.5% in the 3rd quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock worth $55,000 after acquiring an additional 1,068 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Amphastar Pharmaceuticals by 99.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock worth $58,000 after acquiring an additional 628 shares during the period. Finally, Point72 Hong Kong Ltd purchased a new stake in Amphastar Pharmaceuticals in the 1st quarter worth approximately $74,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the sale, the director now directly owns 80,333 shares of the company’s stock, valued at approximately $4,265,682.30. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the transaction, the director now owns 21,326 shares in the company, valued at approximately $1,006,160.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the transaction, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The disclosure for this sale can be found here. In the last three months, insiders sold 14,000 shares of company stock valued at $660,860. Company insiders own 28.40% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 1.3 %

Shares of NASDAQ AMPH opened at $39.62 on Monday. The firm has a fifty day moving average of $47.31 and a 200-day moving average of $51.39. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. Amphastar Pharmaceuticals, Inc. has a 52-week low of $35.62 and a 52-week high of $67.66. The stock has a market capitalization of $1.91 billion, a PE ratio of 15.36, a P/E/G ratio of 0.94 and a beta of 0.84.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. The business had revenue of $178.11 million for the quarter, compared to analysts’ expectations of $174.90 million. On average, analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.42 EPS for the current year.

Analyst Upgrades and Downgrades

AMPH has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. JPMorgan Chase & Co. began coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective for the company. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $66.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.